Please login to the form below

Not currently logged in
Email:
Password:

cHL

This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene takes PD-1 antibody into pivotal trials

China’s BeiGene takes PD-1 antibody into pivotal trials

The single-arm trial enrolled 70 cHL patients who had failed autologous stem cell transplantation (ASCT) – a primary treatment for the cancer – or were ineligible for the procedure.

Latest news

  • Merck suspends two Keytruda trials after patient deaths Merck suspends two Keytruda trials after patient deaths

    Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    cHL), shortly after the FDA cleared the drug for the same blood cancer in the US. ... BMS' Opdivo (nivolumab) - which is already approved in the EU for cHL - was given the nod for the treatment for adults with squamous cell cancer of the head and neck

  • Keytruda claims first blood cancer OK from FDA Keytruda claims first blood cancer OK from FDA

    Merck &Co wins US approval for its haematological cancer treatment. Merck &Co has won FDA clearance for its PD-1 inhibitor Keytruda in classical Hodgkin lymphoma (cHL), the first green light ... The US regulator gave a conditional approval to Keytruda

  • Opdivo gets green light for Hodgkin lymphoma in Europe Opdivo gets green light for Hodgkin lymphoma in Europe

    Less common than non-Hodgkin's lymphoma, cHL affects around 12, 200 people in the EU every year, often being diagnosed in early adulthood. ... BMS says the drug is still showing robust growth in other indications such as melanoma, renal cancer and cHL.

  • BMS wins early UK access for Opdivo in Hodgkin’s lymphoma BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

    The Medicines Healthcare Products and Regulatory Agency (MHRA) approved Opdivo for early access as a monotherapy for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) who have ... In a recent phase II trial, the

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics